Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

T. Geller, Leore; Barzily-Rokni, Michal; Danino, Tal; Jonas, Oliver; Shental, Noam; Nejman, Deborah; Gavert, Nancy; Zwang, Yaara; A. Cooper, Zachary; Shee, Kevin; A. Thaiss, Christoph; Reuben, Alexandre; Livny, Jonathan; Avraham, Roi; T. Frederick, Dennie; Ligorio, Matteo; Chatman, Kelly; Johnston, Stephen; M. Mosher, Carrie; Brandis, Alexander; Fuks, Garold; R. Gurbatri, Candice; Gopalakrishnan, Vancheswaran; P. Kim, Michael; W. Hurd, Mark; H. G. Katz, Matthew; B. Fleming, Jason; Maitra, Anirban; A. Smith, David; Skalak, Matt; Bu, Jeffrey; Michaud, Monia; A. Trauger, Sunia; Barshack, Iris; Golan, Talia; Sandbank, Judith; T. Flaherty, Keith; Mandinova, Anna; S. Garrett, Wendy; P. Thayer, Sarah; R. Ferrone, Cristina; Huttenhower, Curtis; N. Bhatia, Sangeeta; Gevers, Dirk; A. Wargo, Jennifer; R. Golub, Todd; Straussman, Ravid

doi:10.1126/science.aah5043

Public

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

Published in Science • Sep 14, 2017

Authors:

Leore T. Geller

Michal Barzily-Rokni

Tal Danino

Abstract

expression, and abrogated by cotreatment with the antibiotic ciprofloxacin. Gemcitabine is commonly used to treat pancreatic ductal adenocarcinoma (PDAC), and we hypothesized that intratumor bacteria might contribute to drug resistance of these tumors. Consistent with this possibility, we found that...

Subject

Gemcitabine

Drug resistance

Drug

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!